SCYNEXIS, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
SCYNEXIS, Inc. (SCYX) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -3.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-04
- SCYNEXIS, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was -3.00%.
- SCYNEXIS, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -1.20%.
- SCYNEXIS, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was 0.00%.
- SCYNEXIS, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was -1.20%, a 192.31% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -3.00% 10-K · filed 2026-03-04 | |
| 2024-12-31 | -1.20% 10-K · filed 2026-03-04 | -1.10% 10-K · filed 2025-03-12 |
| 2023-12-31 | 0.00% 10-K · filed 2025-03-12 | -0.60% 10-K · filed 2024-03-28 |
| 2022-12-31 | -1.20% 10-K · filed 2024-03-28 | |
| 2021-12-31 | 1.30% 10-K · filed 2023-03-31 | |
| 2020-12-31 | 0.00% 10-K · filed 2022-03-29 | -0.30% 10-K · filed 2021-03-29 |
| 2019-12-31 | -1.50% 10-K · filed 2021-03-29 | |
| 2018-12-31 | -0.30% 10-K · filed 2020-03-11 | -0.34% 10-K · filed 2019-03-14 |
| 2017-12-31 | -3.30% 10-K · filed 2019-03-14 | |
| 2016-12-31 | -2.40% 10-K · filed 2018-03-13 | |
| 2015-12-31 | 0.50% 10-K · filed 2017-03-13 | |
| 2014-12-31 | 2.80% 10-K · filed 2017-03-13 | -1.30% 10-K · filed 2015-03-30 |
| 2013-12-31 | 0.00% 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |